Share this article on:

Polymorphism of RANTES Chemokine Gene Promoter Is Not Associated With Long-Term Nonprogressive HIV-1 Infection of More Than 16 Years

Vidal, Francesc MD, PhD*; Peraire, Joaquim MD*; Domingo, Pere MD, PhD; Broch, Montserrat PhD*; Cairó, Mireia MD; Pedrol, Enric MD, PhD§; Montero, Milagros MD; Viladés, Consuelo MD*; Gutiérrez, Cristina PhD*; Sambeat, Ma Antònia MD, PhD; Fontanet, Àngels; Dalmau, David MD, PhD; Deig, Elisabeth MD§; Knobel, Hernando MD, PhD; Sirvent, Joan Josep MD, PhD*; Richart, Cristóbal MD, PhD* on Behalf of the Chemokines and Long-Term Nonprogressive HIV01 Infection Study Group

JAIDS Journal of Acquired Immune Deficiency Syndromes: January 1st, 2006 - Volume 41 - Issue 1 - p 17-22
doi: 10.1097/01.qai.0000188335.86466.ea
Basic Science

To examine whether polymorphisms of the RANTES chemokine gene promoter are associated with long-term nonprogressive HIV-1 infection in white Spanish subjects, we performed a cross-sectional genetic association case-control study. Two-hundred sixty-seven white Spaniards were studied: 58 were HIV-1-infected long-term nonprogressors (LTNPs) of more than 16 years, 109 were HIV-1-infected usual progressors (UPs), and 100 were control subjects. Three RANTES single nucleotide polymorphisms (SNPs) at positions −28C>G, −109T>C, and −403G>A were assessed. The prevalence of the CCR5Δ 32 allele was also examined. Genotyping was performed using polymerase chain reaction and automatic sequencing analysis methods. Genotype and allele frequencies between the 3 groups were compared by the χ2 test and the Fisher exact test. The distribution of allelic variants of RANTES in controls, UPs, and LTNPs, respectively, was 3%, 2%, and 5% for −28G; 4%, 2%, and 2% for −109C; and 18%, 18%, and 18% for −403A (P = not significant). The differences were still nonsignificant when we exclusively analyzed individuals not carrying the CCR5Δ32 allele. We conclude that LTNP of more than 16 years is not associated with SNPs in the RANTES gene promoter in white Spanish HIV-1-infected subjects.

From the *Hospital Universitari de Tarragona Joan XXIII and Universitat Rovira i Virgili, Tarragona, Spain; †Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain; ‡Unitat VIH. Servei de Malalties Infeccioses. Fundació per a la Recerca. Hospital Mútua de Terrassa. Universitat de Barcelona, Terrasa, Spain; §Hospital General de Granollers, Granollers, Spain; and ∥Hospital del Mar de Barcelona, Barcelona, Spain.

Received for publication August 4, 2005; accepted September 14, 2005.

Partially financed by grants from the Marató de TV3 (02/1830, 02/1831, 02/1832, 02/1833, and 02/1834) and the Spanish AIDS Research Network Red Temática Cooperativa de Investigaciónde Sida G03/173 and Fondo de Investigación Sanitaria 02/1282.

Reprints: Francesc Vidal, Department of Internal Medicine and Infectious Diseases, Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Mallafré Guasch, 4, 43007 Tarragona, Catalonia, Spain (e-mail: fvidal@comt.es).

© 2006 Lippincott Williams & Wilkins, Inc.